

Speakers



Dr Line Lundsberg-Nielsen
NNE



Dr Thomas Schneppe



Dr Franz Schönfeld
GMP Inspector for EMA



Dr Ingolf Stückerath
Sanofi-Aventis Deutschland



Dr Chris Watts
VoPal, formerly with FDA



Sarah Zimmet
Boehringer Ingelheim

Ongoing/Continued Process Verification

From the Control Strategy to Product Quality Review



Live Online Training on 27/28 May 2025



Practical aspects - statistical background

Highlights

- FDA's Process Validation guide and the principles behind
- View of an EU inspector
- Parallels between Medical Device and Drug Process Validation
- Recent trends in FDA inspections, observations and Warning Letters
- The future role of PAT, industrial IT and automation in continued process verification
- Case Studies:
 - From Control Strategy to Trending
 - How to implement CPV of a legacy process (small molecules)
 - Large Molecules: Process Validation and Statistical Trending in Biopharmaceutical Manufacturing
 - SPC as tool for Continued Process Verification

Objective

With the Guidance for Industry “Process Validation: General Principles and Practices”, the FDA requires a new direction. Validation is now a „Life Cycle Process” with 3 stages:

- Process Design
- Process Qualification
- Continued Process Verification

The stage 3 “Continued Process Verification” is a new step in validation. Also legacy process should be (re)validated regarding this life cycle. The start is stage 3 “Continued Process Verification”. The goal of the third validation stage is continual assurance that the process remains in a state of control (the validated state) during commercial manufacture. A system or systems for detecting unplanned departures from the process as designed is essential to accomplish this goal, says the Guidance. **Now, also the EU requires Ongoing Process Verification as part of a validation lifecycle.**

But how to implement Continued/Ongoing Process Verification in the routine production – **beginning from the definition of the control strategy to the Product Quality Review/Annual Product Review (APR)?**

- What is state of the art regarding systems for detecting unplanned departures from the process?
- How to handle the monitoring at Stage 3 (Continued/Ongoing Process Verification)?
- What are the differences between Continued Process Verification (FDA), Continuous Process Verification (ICH Q8) and Ongoing Process Verification (EU)?
- Are there parallels regarding Medical Devices?
- What statistic parameters could help?
- Is a statistician necessary?
- How is OPV/CPV linked to PQR/APR?
- What are the expectations of an EU Inspector?

These questions are discussed, and the possibilities for implementation are covered.

Background

Since 1987 the FDA Guideline on Process Validation has been the basis for qualification and validation. A new FDA Policy Guide of 2004 gives some hints as to the new validation approach. In January 2011 the new “Guidance for Industry Process Validation: General Principles and Practices” was published as final guidance. That is now FDA’s „current thinking“. EMA’s new Process Validation Guidance also mentions a Life Cycle Approach for Process Validation. And with the citation of ICH Q8, the possibility to do Continuous Process Verification is also mentioned. **In the Annex 15 revision document, valid since 1 October 2015, also a Continued Process Verification, called Ongoing Process Verification, is now a requirement.**

Target Audience

The addressees of the event are qualified staff charged with or responsible for validation activities, especially regarding stage 3 (Continued/Ongoing Process Verification) of the Process Validation Life Cycle. We mean commissioners for validation, heads of quality assurance, department heads, etc. It also addresses members of validation teams (e.g. chemists, pharmacists, microbiologists) as well as staff who is involved in process monitoring activities and consultants.

Programme

Overview: The new Process Validation Guides from FDA and EMA and the new Industry Guides from ISPE, PDA and ECA: Content and Principles

- How the concept of Process Validation is about to change
- Comparison of Annex 15 revision with FDA Process Validation Guidance
- Real-life examples

Ongoing Process Verification – View of an EU Inspector

- EU Process Validation lifecycle approach (overview)
- EU GMP requirements on EU-OPV
- Authorities expectations reg. PQR and link to OPV
- Comparison of EU and US requirements reg. OPV/CPV



Case Study: From Control Strategy to Trending

- Introduction in Biopharmaceutical Processes
- Process development and definition of parameters
- Parameters and control
- Control Strategy
- Process Performance Validation Approach
- Statistical Process Control



Case Study: Large Molecules - Process Validation and Statistical Trending in Biopharmaceutical Manufacturing

- Basic Statistics
- Content of CPV protocol/report
- Trending program and related procedures
- Evaluation of Trends and CAPAs
- Link to APR/PQR
- Link to IT System

Medical Device and Pharmaceuticals: Similar Expectations and Approaches

- Leveraging experience
- Quality System similarities
- Standard Approaches – foundation for implementation

Recent Trends in FDA Inspections, Observations and Warning Letters

- Examples of expectations and enforcement
- Regulatory enforcement trends related to observations and Warning Letters

SPC as Tool for Continued Process Verification

- Continued Process Verification: Requirements
- Case Study Sanofi-Aventis



Case Study: How to implement CPV of a Legacy Process

- Challenges
- Experiences
- Lessons learnt

The future role of PAT, industrial IT and Automation in Continued Process Verification: Implementing a Control Strategy

- Control Strategy and implications for automation solutions
- Bridging islands of information systems in manufacturing
- From data to information to knowledge: getting gold out of data
- Continued process verification: monitoring challenges
- Window to the Quality: The future role of automation and IT systems in manufacturing?

Speakers

Dr Line Lundsberg-Nielsen, NNE, Denmark

Line is a scientist and runs her own consultancy business focusing on applying a science and risk based approach for pharmaceutical development, process design, technology transfer, qualification and process validation. She has many years of experience within the pharmaceutical Industry and has a theoretical as well as practical approach to QbD, PAT and RTRT from working at Novo Nordisk and Lundbeck before being a consultant. Line is an active ISPE member and has had different chairing roles and is a well-recognized international speaker and instructor.

Dr Thomas Schneppe

Thomas has more than 35 years GMP experience in Pharmaceutical Industry: Qualified Person, Mgmt. Training, GMP Projects, Operational Excellence in different functions at Klöckner Pentapack, Schering AG, Asche AG, Bayer AG, Bayer Bitterfeld GmbH and actually as freelance consulting for QM and GMP compliance.

Dr Franz Schönfeld, GMP Inspector, District Government of Upper Bavaria, Germany

Dr Franz Schönfeld is a GMP and GDP inspector at the local inspectorate for medicinal products and active substances of the District Government of Upper Franconia. He is head of the expert working group for APIs at the Central Authority of the Federal States for Health Protection.

Dr Ingolf Stückrath, Sanofi-Aventis Deutschland, Germany

Today Ingolf is responsible for a major insulin production facility in Frankfurt. He began his career with Aventis in 2000 and was among others Six Sigma Black Belt, was responsible for all Industrial Excellence activities at the site. In 2005 his work was recognized with the IQPC's Six Sigma IQ Excellence Award in the category "Best Defect Elimination in Manufacturing". He holds a Ph. D. in biology.

Dr Chris Watts, Principal Consultant, VolPal, USA

Chris Watts is a principal consultant within quality and regulatory, having gained experience both from industry and FDA. Chris was part of the team at the FDA that developed the Agency's modern approach to quality and compliance. These included the science and risk-based approach to cGMP inspection and CMC application review, including the recent ICH Quality guidelines and the FDA guidance on Process Validation.

Sarah Zimmet, Boehringer Ingelheim, Germany

Sarah Zimmet studied human and molecular biology, started working with Boehringer Ingelheim in 2016 and is a member of Process & Cleaning Validation Drug Substance. As Validation Manager she gained a deep insight in general challenges in Continued Process Verification (stage 3) such as revalidation activities, control strategy as well as monitoring and trending.



Stay informed with the GMP Newsletters from ECA

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, simply scan the QR code on the right or visit www.gmp-compliance.org/gmp-newsletter



If the bill-to-address deviates from the specifications on the right, please fill out here:

Reservation Form (Please complete in full)



Ongoing/Continued Process Verification – from the control strategy to Product Quality Review Live Online Training on 27/28 May 2025

Title, first name, surname

Department

Company

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

ZIP Code

Country

Phone / Fax

E-Mail (Please fill in)

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg
GERMANY

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
 - Cancellation until 4 weeks prior to the conference 10 %
 - Cancellation until 3 weeks prior to the conference 25 %
 - Cancellation until 2 weeks prior to the conference 50 %
 - Cancellation within 2 weeks prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation. **Terms of payment:** Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of can-

cellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed!) (As of July 2022).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.



Date of the Live Online Training

Tuesday, 27 May 2025, 09.00 - 16.45 h

Wednesday, 28 May 2025, 08.30 - 16.30 h

All times mentioned are CEST.

Technical Requirements

We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate, plus VAT)

ECA Members € 1,890

APIC Members € 1,990

Non-ECA Members € 2,090

EU GMP Inspectorates € 1,045

The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

You cannot attend the Live Event?

We also offer many of the training courses and conferences as recordings. This means that you can watch the videos of the event „on demand“ – whenever it suits you – on our web server. It is quite uncomplicated and doesn't require any software – you simply watch the video on your browser. You can find all recorded events at www.gmp-compliance.org/recordings.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG

P.O. Box 10 17 64

69007 Heidelberg, Germany

Phone +49(0)62 21/84 44-0

Fax +49(0)62 21/84 44 34

info@concept-heidelberg.de

www.concept-heidelberg.de

For questions regarding content please contact:

Mr Sven Pommeranz (Operations Director) at

+49(0)62 21/84 44 47, or at

pommeranz@concept-heidelberg.de.

For questions regarding organisation please contact:

Ms Sonja Nemeč (Organisation Manager) at

+49(0)62 21/84 44 24, or at

nemec@concept-heidelberg.de.